Erasca ERAS-0015 R&D Push Widens Q3 2026 Loss Beyond Estimates
As seen on the 24/7 Wall St. homepage on November 12, 2026.
The wider loss is deliberate: R&D spending more than doubled to $47.2 million as Erasca pushes pan-RAS drug ERAS-0015 toward three registration-enabling trials in pancreatic and lung cancer. Updated monotherapy data lands at the ENA Symposium November 18.
Continue ReadingShow less
Erasca reported a GAAP loss of $0.15 per share for Q3 2026, missing expectations. The gap was entirely intentional: the company is in an aggressive build phase ahead of what it expects to be three registration-enabling trials for its lead drug candidate.
R&D spending more than doubled to $47.2 million, the single biggest driver of the widening loss. General and administrative expenses also rose, while interest income climbed, partially offsetting the increased spending.
The drug at the center of that spending is ERAS-0015, a pan-RAS molecular glue being developed for patients with RAS-mutant pancreatic and lung cancers, which carry high unmet need and limited existing treatment options. In August 2026, the FDA granted ERAS-0015 Fast Track Designation for metastatic pancreatic adenocarcinoma, giving Erasca the opportunity for more frequent agency interactions as the program advances.
Sponsored
Erasca's balance sheet gives it room to execute the plan. A public offering completed in July 2026 lifted cash, equivalents, and marketable securities to $947.8 million. Management stated that balance is sufficient to fund all key upcoming milestones, including Phase 3 pivotal trial starts in first-line pancreatic cancer and RAS-mutant non-small cell lung cancer expected in 2027.
Updated ERAS-0015 monotherapy data from the AURORAS-1 Phase 1 trial is scheduled for an oral plenary presentation at the ENA Symposium on November 18, 2026, alongside nonclinical data combining ERAS-0015 with ERAS-4001. Phase 1 monotherapy expansion data and combination dose-escalation data are both expected to follow in the first half of 2027. Revolution Medicines has alleged that ERAS-0015 infringes its patents or was derived from its trade secrets, an overhang the market will continue to monitor alongside clinical progress.
Mentioned: ERAS